Denmark based pharmaceutical firm Novo Nordisk launchedit’s combination diabetic drugRyzodeg, priced at Rs 1,595 for 300 units, for people with type II diabetes in India.
Novo Nordisk Corporate VP for Business Area Africa, Gulf & India, Mads Bo Larsen said: “India has close to 65.1 million people with diabetes standing second in the world map….We are extremely pleased to have introduced Ryzodeg reinforcing our commitment to provide best of healthcare solutions for the use of doctors in India.”
As Ryzodeg is a combination product it requires fewer daily injections than administering basal and mealtime insulin in separate injections, Novo Nordisk said.
“For more than 90 years, Novo Nordisk has been leading the fight against diabetes by developing the most innovative products based on patient needs. The launch of Ryzodeg builds on this heritage as it is an innovative product that will give the health care professional a better way to manage the condition,” Novo Nordisk India MD Melvin Oscar D’souza said.
The product is a combination of two distinct insulin analogues (insulin degludec and insulin aspart in the ratio of 70 per cent and 30 per cent),the company said.
Diabetes is a group of diseases marked by high levels of blood sugar (glucose) caused by problems with the body’s ability to produce or properly use insulin, or both.
Headquartered in Denmark, Novo Nordisk employs around 41,000 employees in 75 countries, and markets its products in more than 180 countries.